Nomusa Walther
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nomusa Walther has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Ad Vos
IDT Biologika GmbH, Dessau-Rosslau, Germany
1 shared publication - Antje Kretzschmar
IDT Biologika GmbH, Dessau Rosslau, Germany
1 shared publication - Christiane Kaiser
IDT Biologika GmbH, Dessau Rosslau, Germany
1 shared publication - Conrad Martin Freuling
Institute of Molecular Virology and Cell Biology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany
1 shared publication - Ivana Lojkić
Croatian Veterinary Institute, Savska cesta 143, 10000 Zagreb, Croatia
1 shared publication - Steffen Ortmann
IDT Biologika GmbH, 06861 Dessau, Rosslau, Germany
1 shared publication
Latest Publications
- Open Access
- 13 March 2018
- Published by Springer Nature in BMC Veterinary Research
- Vol. 14 (1) , 1-7
Safety studies with the oral rabies virus vaccine strain SPBN GASGAS in the small Indian mongoose (Herpestes auropunctatus)
Oral vaccination of the small Indian mongoose against rabies has been suggested as a potential tool to eliminate mongoose-mediated rabies on several Caribbean islands. A recently developed oral rabies virus vaccine strain, SPBN GASGAS, has already been shown to be efficacious in this reservoir species. Since, all available oral rabies vaccines are based on replication-competent viruses and vaccine baits are distributed unsupervised in the environment, enhanced safety standards for such vaccine types are required. The results of safety studies, including overdose, repeated doses, dissemination and different routes of administration, in the target species are presented. It was shown that the construct was apathogenic, irrespective of dose and route of administration. Even when it was inoculated directly in the brain, it did not induce rabies infection. Furthermore, the vaccine strain did not spread within the target species after direct oral instillation beyond the site of entry. The vaccine strain SPBN GASGAS meets the safety requirements for live rabies virus vaccines in this target species, the small Indian mongoose.
- 13 March 2018
- Published by Springer Nature in BMC Veterinary Research
- Vol. 14 (1) , 1-7
Open AccessSafety studies with the oral rabies virus vaccine strain SPBN GASGAS in the small Indian mongoose (Herpestes auropunctatus)
Oral vaccination of the small Indian mongoose against rabies has been suggested as a potential tool to eliminate mongoose-mediated rabies on several Caribbean islands. A recently developed oral rabies virus vaccine strain, SPBN GASGAS, has already been shown to be efficacious in this reservoir species. Since, all available oral rabies vaccines are based on replication-competent viruses and vaccine baits are distributed unsupervised in the environment, enhanced safety standards for such vaccine types are required. The results of safety studies, including overdose, repeated doses, dissemination and different routes of administration, in the target species are presented. It was shown that the construct was apathogenic, irrespective of dose and route of administration. Even when it was inoculated directly in the brain, it did not induce rabies infection. Furthermore, the vaccine strain did not spread within the target species after direct oral instillation beyond the site of entry. The vaccine strain SPBN GASGAS meets the safety requirements for live rabies virus vaccines in this target species, the small Indian mongoose.